| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
OPEN ACCESS ARTICLE
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TRANSLATIONAL AND CLINICAL RESEARCH |
aInstitut National de la Santé et de la Recherche Médicale, Montpellier, France;
bUniversity of Montpellier I, Montpellier, France
Key Words. Multipotent stromal cells • Mesenchymal stem cells • Cellular therapy • Cancer • Cellular proliferation • Angiogenesis • Chemokines
Correspondence: Correspondence: Gwendal Lazennec, Ph.D., INSERM, U844, Site Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, BP 74103, 34091 Montpellier cedex 5, France; University of Montpellier I, Montpellier, France. Telephone: 33-4-99-63-60-27; Fax: 33-4-99-63-60-20; e-mail: Gwendal.Lazennec{at}inserm.fr
Received on November 29, 2007;
accepted for publication on March 22, 2008.
First published online in STEM CELLS EXPRESS April 3, 2008.
This review focuses on the interaction between multipotent stromal cells (MSCs) and carcinoma and the possible use of MSCs in cell-based anticancer therapies. MSCs are present in multiple tissues and are defined as cells displaying the ability to differentiate in multiple lineages, including chondrocytes, osteoblasts, and adipocytes. Recent evidence also suggests that they could play a role in the progression of carcinogenesis and that MSCs could migrate toward primary tumors and metastatic sites. It is possible that MSCs could also be involved in the early stages of carcinogenesis through spontaneous transformation. In addition, it is thought that MSCs can modulate tumor growth and metastasis, although this issue remains controversial and not well understood. The immunosuppressive properties and proangiogenic properties of MSCs account, at least in part, for their effects on cancer development. On the other hand, cancer cells also have the ability to enhance MSC migration. This complex dialog between MSCs and cancer cells is certainly critical for the outcome of tumor development. Interestingly, several studies have shown that MSCs engineered to express antitumor factors could be an innovative choice as a cell-mediated gene therapy to counteract tumor growth. More evidence will be needed to understand how MSCs positively or negatively modulate carcinogenesis and to evaluate the safety of MSC use in cell-mediated gene strategies.
Disclosure of potential conflicts of interest is found at the end of this article.
This article has been cited by other articles:
|
|
 |
|
  C. Bouffi, F. Djouad, M. Mathieu, D. Noel, and C. Jorgensen Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit? Rheumatology, June 26, 2009; (2009) kep162v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, A. Daquinag, D. O. Traktuev, F. Amaya-Manzanares, P. J. Simmons, K. L. March, R. Pasqualini, W. Arap, and M. G. Kolonin White Adipose Tissue Cells Are Recruited by Experimental Tumors and Promote Cancer Progression in Mouse Models Cancer Res., June 15, 2009; 69(12): 5259 - 5266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Compte, A. M. Cuesta, D. Sanchez-Martin, V. Alonso-Camino, J. L. Vicario, L. Sanz, and L. Alvarez-Vallina Tumor Immunotherapy Using Gene-Modified Human Mesenchymal Stem Cells Loaded into Synthetic Extracellular Matrix Scaffolds Stem Cells, March 1, 2009; 27(3): 753 - 760. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
